This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2013 Jul;59(7):253-60.

doi: 10.1016/j.disamonth.2013.03.012.

Management of multiple sclerosis: an overview

PMID: 23786659
DOI: 10.1016/j.disamonth.2013.03.012

Review

Management of multiple sclerosis: an overview

Susan M Rubin. Dis Mon. 2013 Jul.

. 2013 Jul;59(7):253-60.

doi: 10.1016/j.disamonth.2013.03.012.

Author

PMID: 23786659
DOI: 10.1016/j.disamonth.2013.03.012

No abstract available

PubMed Disclaimer

Similar articles

Use of interferon-beta in the treatment of multiple sclerosis.
Derwenskus J, Lublin FD. Derwenskus J, et al. Adv Neurol. 2006;98:257-71. Adv Neurol. 2006. PMID: 16400838 Review. No abstract available.
[Interferon therapy of multiple sclerosis. Synopsis of various dosage forms].
Jarius S, Hohlfeld R. Jarius S, et al. Nervenarzt. 2004 Dec;75(12):1226-30. doi: 10.1007/s00115-004-1834-0. Nervenarzt. 2004. PMID: 15565383 Review. German.
Pharmacologic management of multiple sclerosis.
Blasier MG. Blasier MG. Urol Nurs. 2008 Jun;28(3):217-9. Urol Nurs. 2008. PMID: 18605517 No abstract available.
Is natalizumab overshooting its rebound?
Fox RJ, Kappos L. Fox RJ, et al. Neurology. 2008 Mar 25;70(13 Pt 2):1073-4. doi: 10.1212/01.wnl.0000306415.37679.5a. Neurology. 2008. PMID: 18362270 No abstract available.
Multiple sclerosis treatment: current best practice.
Niino M. Niino M. Expert Rev Clin Immunol. 2012 Aug;8(6):505-7. doi: 10.1586/eci.12.38. Expert Rev Clin Immunol. 2012. PMID: 22992142 No abstract available.

See all similar articles

Cited by

CXCL10 Chemokine: A Critical Player in RNA and DNA Viral Infections.
Elemam NM, Talaat IM, Maghazachi AA. Elemam NM, et al. Viruses. 2022 Nov 3;14(11):2445. doi: 10.3390/v14112445. Viruses. 2022. PMID: 36366543 Free PMC article. Review.
Nocturia in Patients With Multiple Sclerosis.
Peyronnet B, Krupp LB, Reynolds WS, Gamé X, Amarenco G, Cornu JN, Ryerson LZ, Sammarco CL, Howard JE, Charlson RW, Dmochowski RR, Brucker BM. Peyronnet B, et al. Rev Urol. 2019;21(2-3):63-73. Rev Urol. 2019. PMID: 31768133 Free PMC article.
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.
Burks J, Marshall TS, Ye X. Burks J, et al. Clinicoecon Outcomes Res. 2017 Apr 28;9:251-260. doi: 10.2147/CEOR.S130334. eCollection 2017. Clinicoecon Outcomes Res. 2017. PMID: 28496344 Free PMC article.
Secondary and tertiary treatments for multiple sclerosis patients with urinary symptoms.
Tracey JM, Stoffel JT. Tracey JM, et al. Investig Clin Urol. 2016 Nov;57(6):377-383. doi: 10.4111/icu.2016.57.6.377. Epub 2016 Oct 24. Investig Clin Urol. 2016. PMID: 27847911 Free PMC article. Review.
Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis.
Yetkin MF, Mirza M, Dönmez H. Yetkin MF, et al. Medicine (Baltimore). 2016 Sep;95(36):e4782. doi: 10.1097/MD.0000000000004782. Medicine (Baltimore). 2016. PMID: 27603381 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information